Amgen’s phase 3 VESALIUS-CV trial meets primary endpoints in a cardiovascular primary prevention study of 12,000 patients: Thousand Oaks, California Saturday, October 4, 2025, 1 ...
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback